| Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma Y de Jong, D Monderer, E Brandinelli, M Monchanin, BE van den Akker, ... Oncogenesis 7 (9), 74, 2018 | 62 | 2018 |
| Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin Z Baranski, Y de Jong, T Ilkova, EFP Peterse, AM Cleton-Jansen, ... Oncotarget 6 (34), 36113, 2015 | 51 | 2015 |
| NAD synthesis pathway interference is a viable therapeutic strategy for chondrosarcoma EFP Peterse, BEWM van den Akker, B Niessen, J Oosting, J Suijker, ... Molecular Cancer Research 15 (12), 1714-1721, 2017 | 50 | 2017 |
| Molecular oncogenesis of chondrosarcoma: impact for targeted treatment FM Speetjens, Y de Jong, H Gelderblom, JVMG Bovée Current opinion in oncology 28 (4), 314-322, 2016 | 50 | 2016 |
| Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation EFP Peterse, B Niessen, RD Addie, Y de Jong, AHG Cleven, ... British journal of cancer 118 (8), 1074-1083, 2018 | 48 | 2018 |
| Targeting survivin as a potential new treatment for chondrosarcoma of bone Y De Jong, JG Van Oosterwijk, AB Kruisselbrink, IH Briaire-de Bruijn, ... Oncogenesis 5 (5), e222-e222, 2016 | 47 | 2016 |
| Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes Y de Jong, M Ingola, IH Briaire-de Bruijn, AB Kruisselbrink, S Venneker, ... Clinical sarcoma research 9, 1-11, 2019 | 44 | 2019 |
| Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line Y de Jong, AM van Maldegem, A Marino-Enriquez, D de Jong, J Suijker, ... Laboratory investigation 96 (10), 1128-1137, 2016 | 40 | 2016 |
| MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1/2 phosphorylation Z Baranski, TH Booij, ML Kuijjer, Y de Jong, AM Cleton-Jansen, LS Price, ... Genes & Cancer 6 (11-12), 503, 2015 | 37 | 2015 |
| Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo-and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status S Venneker, AB Kruisselbrink, IH Briaire-de Bruijn, Y de Jong, ... Cancers 11 (12), 1918, 2019 | 28 | 2019 |
| Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway RD Addie*, Y de Jong*, G Alberti, AB Kruisselbrink, I Que, H Baelde, ... Journal of Bone Oncology, 100222, 2019 | 26 | 2019 |
| High-Level MYCN-Amplified RB1-Proficient Retinoblastoma Tumors Retain Distinct Molecular Signatures K Roohollahi, Y de Jong, SE van Mil, AWM Fabius, AC Moll, JC Dorsman Ophthalmology science 2 (3), 100188, 2022 | 15 | 2022 |
| High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth MA de Graaff, S Malu, I Guardiola, AB Kruisselbrink, Y de Jong, ... Translational oncology 10 (4), 546-554, 2017 | 13 | 2017 |
| BIRC2–BIRC3 amplification: a potentially druggable feature of a subset of head and neck cancers in patients with Fanconi anemia K Roohollahi, Y de Jong, G Pai, MA Zaini, K de Lint, D Sie, MA Rooimans, ... Scientific Reports 12 (1), 1-17, 2022 | 9 | 2022 |
| A screening-based approach identifies cell cycle regulators AURKA, CHK1 and PLK1 as targetable regulators of chondrosarcoma cell survival Y de Jong, F Bennani, JG van Oosterwijk, G Alberti, Z Baranski, ... Journal of Bone Oncology 19, 100268, 2019 | 9 | 2019 |
| No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone EFP Peterse, AHG Cleven, Y De Jong, I Briaire-de Bruijn, JA Fletcher, ... BMC cancer 16, 1-11, 2016 | 8 | 2016 |
| Molecular Drivers in Chondrosarcoma Y de Jong, JVMG Bovée Chordomas and Chondrosarcomas of the Skull Base and Spine, 31-41, 2018 | 4 | 2018 |
| Correlation of gene expression with magnetic resonance imaging features of retinoblastoma: a multi-center radiogenomics validation study RW Jansen, K Roohollahi, OE Uner, Y de Jong, CM de Bloeme, S Göricke, ... European Radiology 34 (2), 863-872, 2024 | 1 | 2024 |
| Genome-wide siRNA screens identify RBBP9 function as a potential target in Fanconi anaemia-deficient head-and-neck squamous cell carcinoma G Pai, K Roohollahi, D Rockx, Y de Jong, C Stoepker, C Pennings, ... Communications Biology 6 (1), 37, 2023 | | 2023 |
| A screening based approach to find new paths for targeted treatment in chondrosarcoma Y de Jong Leiden University, 2020 | | 2020 |
